Foresta (ASX:FGH) Wins Japanese Patent Acceptance for Pine Chemical Extraction

Sonal Goyal

26 October 2026 03:01 PM AEDT

Foresta (ASX:FGH) Wins Japanese Patent Acceptance for Pine Chemical Extraction

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

A Japanese patent covering rosin and terpene extraction was accepted.
A NZ$150,050 research project was agreed with the Bioeconomy Science Institute.
Cash was $2,472,267 at 30 September 2026.
Foresta now has two patent families.

Foresta Group Holdings Limited (ASX:FGH) released its quarterly activities report and Appendix 4C for the quarter ending 30 September 2026 on 26 October 2026, reporting acceptance of a Japanese patent for its pine chemical extraction technology and a research collaboration in New Zealand.

Japanese patent

Japanese Patent Application No. 2022-577621, covering Foresta's rosin and terpene extraction technology, has been accepted. It protects elements of the pine chemical production process, including extraction using a rotary extractor under specified operating conditions. A divisional application covering counter-current treatment of wood with a terpene-based extraction agent is progressing, and similar claims are being pursued in Europe and China.

Research collaboration

Foresta agreed a collaboration with the Bioeconomy Science Institute to quantify and characterise rosin and turpentine extractives in radiata pine stems, stumps and branches across growing regions. The NZ$150,050 project is supported by the Bioresource Processing Alliance, which is funded by New Zealand's Ministry of Business, Innovation and Employment, with NZ$54,150 contributed by the alliance, NZ$54,150 in cash from Foresta and about NZ$41,750 in kind.

Cash position

Foresta held cash of $2,472,267 at 30 September 2026. The company has two patent families, one covering pine wood processing and another covering production of torrefied wood pellets and briquettes.

Company technology background

Foresta's patent filings cover a proprietary pine chemical production process using a rotary extractor and a counter-current treatment of wood with a terpene-based agent, with similar claims pursued in Europe and China. The second patent family relates to production of torrefied wood pellets and briquettes.

The collaboration aims to quantify and characterise rosin and turpentine extractives across radiata pine stems, stumps and branches in different New Zealand growing regions, which relates to the feedstock for the extraction process. The announcement also reported that payments to related parties and their associates consisted entirely of gross remuneration paid in cash.

Why This Could Matter

A granted or accepted patent defines the processes the company can protect in a market, and Japan is one of several jurisdictions where it is seeking coverage. The research project supplies measurements of extractives in different pine components and regions, which relate to the feedstock for the pine chemical process.

Summing Up

Foresta (ASX:FGH) secured Japanese patent acceptance and a funded New Zealand research project in the September 2026 quarter, ending with cash of $2.47 million.

FAQs

Q: What was accepted in Japan?

A: Patent Application No. 2022-577621 covering Foresta's rosin and terpene extraction process.

Q: Who is Foresta partnering with?

A: The Bioeconomy Science Institute, supported by the Bioresource Processing Alliance.

Q: What is the project cost?

A: NZ$150,050 in total.

Q: What was the cash balance?

A: $2,472,267 at 30 September 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.